Real-world registry data from Germany show apremilast improves psoriasis severity and quality of life, with a safety profile consistent with clinical trials.

Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced ...

Optum notable drugs nearing FDA approval include Anaphylm, Sotyktu, and insulin icodec with decisions expected early 2026.

In a separate development, Eli Lilly and Company (NYSE:LLY) announced on January 7 that it entered into a definitive ...

Approximately 20% to 30% of all people who suffer from psoriasis also develop painful inflammation in their joints over time.

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

SKYWAY (NCT07148414) is a Phase 2 basket trial of SPY072 (anti-TL1A) in patients with moderate to severely active RA, PsA, or axSpA. Enrollment is on track, and all indications are expected to readout ...

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

In a phase IIIb trial of adults with active psoriatic arthritis (PsA) and obesity or overweight, adding the GLP-1 drug ...

Eli Lilly said combining Taltz and Zepbound improved arthritis symptoms and drove meaningful weight loss, outperforming Taltz ...